ICP
ATRC icon

Interchange Capital Partners’s AtriCure ATRC Stock Holding History

Interchange Capital Partners’s Portfolio ATRC Stock Details ATRC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-312
Closed -$17K – 293
2020
Q4 		$17K Buy
+312
New +$13.5K 0.01% 669

Other funds holding ATRC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Interchange Capital Partners's ATRC Position: Q1 2021 in Review

Interchange Capital Partners sold out of AtriCure (ATRC) in Q1 2021, closing a stake of 312 shares — an estimated $17K sold.

Interchange Capital Partners first reported a position in ATRC in Q4 2020 and held it in 1 quarter. The position peaked at $17K in Q4 2020. 191 funds tracked by Wall St. Rank hold ATRC as of Q1 2021.

  • Interchange Capital Partners reported no remaining AtriCure position as of Q1 2021 after selling out during the quarter.
  • Interchange Capital Partners sold 312 AtriCure shares in Q1 2021, an estimated $17K.
  • Interchange Capital Partners first reported a position in AtriCure in Q4 2020 and held it in 1 quarter.
  • Interchange Capital Partners's AtriCure position peaked at $17K in Q4 2020.
  • 191 funds tracked by Wall St. Rank held AtriCure as of Q1 2021.

Based on Interchange Capital Partners's 13F filing for Q1 2021, filed 5 May 2021.